Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Schaefer, N. (Niklaus) | - |
dc.creator | Grözinger, G. (Gerd) | - |
dc.creator | Pech, M. (Maciej) | - |
dc.creator | Pfammatter, T. (Thomas) | - |
dc.creator | Soydal, C. (Cigdem) | - |
dc.creator | Arnold, D. (Dick) | - |
dc.creator | Kolligs, F. (Frank) | - |
dc.creator | Maleux, G. (Geert) | - |
dc.creator | Munneke, G. (Graham) | - |
dc.creator | Peynircioglu, B. (Bora) | - |
dc.creator | Sangro, B. (Bruno) | - |
dc.creator | Pereira, H. (Helena) | - |
dc.creator | Zeka, B. (Bleranda) | - |
dc.creator | Jong, N. (Niels) de | - |
dc.creator | Helmberger, T. (Thomas) | - |
dc.date.accessioned | 2023-04-19T09:28:32Z | - |
dc.date.available | 2023-04-19T09:28:32Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Schaefer, N.; Groezinger, G.; Pech, M.; et al. "Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: results from the multicentre observational study CIRT". Clinical Colorectal Cancer. 21 (4), 2022, 285 - 296 | es |
dc.identifier.issn | 1533-0028 | - |
dc.identifier.uri | https://hdl.handle.net/10171/66015 | - |
dc.description.abstract | This study explored factors that can predict effectiveness outcomes after transarterial radioembolization in colorectal liver metastases in the liver. In a cohort of 237 patients, among other factors, we found that an Aspartate transaminase to Platelet Ratio Index (APRI) value of > 0.40 was a particularly strong independent predictor of worse overall survival, progression-free survival and hepatic progression-free survival outcomes. Background: Transarterial radioembolisation (TARE) with Yttrium-90 resin microspheres is a treatment option for patients with metastatic colorectal cancer in the liver (mCRC). A better understanding of the prognostic factors and treat-ment application can improve survival outcomes. Methods: We analysed the safety and effectiveness of 237 mCRC patients included in the prospective observational study CIRSE Registry for SIR-Spheres Therapy (CIRT) for indepen-dent prognostic factors for overall survival (OS), progression-free survival (PFS) and hepatic progression-free survival (hPFS) using the Cox proportional-hazard model. Results: The median OS was 9.8 months, median PFS was 3.4 months and median hPFS was 4.2 months. Independent prognostic factors for an improved overall survival were the absence of extra-hepatic disease ( P = .0391), prior locoregional procedures ( P = .0037), an Aspartate transaminase to Platelet Ratio Index (APRI) value of <= 0.40 ( P < .0001) and Inter national Nor malized Ratio (INR) <= 1 ( P = .0078). Partition model dosimetry resulted in improved OS outcomes compared to the body surface area model ( P = .0120). Independent predictors for PFS were APRI > 0.40 ( P = .0416) and prior ablation ( P = .0323), and for hPFS these were 2 to 5 tumor nodules ( P = .0148), Albumin-bilirubin (ALBI) grade 3 ( P = .0075) and APRI > 0.40 ( P = .0207). During the study, 95 of 237 (40.1%) patients experienced 197 adverse events, with 28 of 237 (11.8%) patients having a grade 3 or higher adverse events. Conclusion: Including easy-to-acquire laboratory markers INR, APRI, ALBI and using partition model dosimetry can identify mCRC patients that may benefit from TARE. | - |
dc.description.sponsorship | The CIRT study was funded by an independent investigator-initiated research grant from SIRTEX Medical Europe GmbH (Bonn, Germany). | - |
dc.language.iso | en | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.subject | Liver | - |
dc.subject | Registry | - |
dc.subject | SIRT | - |
dc.subject | Radiotherapy | - |
dc.subject | Yttrium-90 | - |
dc.title | Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: results from the multicentre observational study CIRT | - |
dc.type | info:eu-repo/semantics/article | - |
dc.description.note | This is an open access article under the CC BY-NC-ND license | - |
dc.identifier.doi | 10.1016/j.clcc.2022.09.002 | - |
dadun.citation.endingPage | 296 | - |
dadun.citation.number | 4 | - |
dadun.citation.publicationName | Clinical Colorectal Cancer | - |
dadun.citation.startingPage | 285 | - |
dadun.citation.volume | 21 | - |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.